Alliance Pharma PLC Completion of acquisition of Vamousse (3992A)

TIDMAPH

RNS Number : 3992A

Alliance Pharma PLC

28 December 2017

 
 For immediate release   28 December 2017 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Completion of acquisition of Vamousse(R)

On 4 December 2017 Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, had entered into an agreement to acquire the worldwide rights to Vamousse from TyraTech Inc (AIM: TYR and TYRU) (the "Acquisition").

Further to Tyratech's announcement on 27 December 2017 that its shareholders have approved the Acquisition, Alliance is pleased to announce that it has today completed the Acquisition.

Alliance is also pleased to announce the appointment of Amanda Sicvol as Country Manager for its newly created US affiliate. Amanda has been instrumental in the commercial success of Vamousse to date, having worked for Tyratech for four years. She brings significant expertise and considerable knowledge of the Vamousse brand.

John Dawson, Alliance Pharma's Chief Executive Officer, commented: "The completion of this acquisition provides Alliance a third International star brand with best in class technology. There is also real potential for further growth through our substantial global network of distributors. We are delighted to welcome Amanda to Alliance to establish our presence in the US, the largest consumer healthcare market in the world."

- Ends -

For further information:

 
                                                    + 44 (0) 1249 
 Alliance Pharma plc                                       466966 
 John Dawson, Chief Executive 
  Officer 
  Peter Butterfield, Deputy Chief 
  Executive Officer 
  Andrew Franklin, Chief Financial 
  Officer 
 www.alliancepharma.co.uk 
                                                 + 44 (0) 20 7466 
 Buchanan                                                    5000 
 Mark Court / Sophie Wills / 
  Gemma Mostyn-Owen 
 
                                                 + 44 (0) 20 7260 
 Numis Securities Limited                                    1000 
 Nominated Adviser: Michael 
  Meade / Freddie Barnfield 
 Corporate Broking: James Black 
  / Toby Adcock 
 
                                                  [phone] 
 Investec Bank plc                                           5970 
 Corporate Finance: Daniel Adams 
  / Ed Thomas 
  Corporate Broking: Patrick 
  Robb / Rob Baker 
 

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical company based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACQDDBDDRUDBGRR

(END) Dow Jones Newswires

December 28, 2017 02:00 ET (07:00 GMT)